1 |
Alzheimer's Association. 2016 Alzheimer's disease facts and figures. Alzheimers Dement 2016;12:459-509.
DOI
|
2 |
Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol 2014;88:640-51.
DOI
|
3 |
Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci U S A 1997;94:2642-7.
DOI
|
4 |
Lezana JP, Dagan SY, Robinson A, Goldstein RS, Fainzilber M, Bronfman FC, et al. Axonal promotes neuronal regeneration after injury. Dev Neurobiol 2016;76:688-701.
DOI
|
5 |
Kumar A, Singh A, Ekavali. A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacol Rep 2015;67:195-203.
DOI
|
6 |
Valerio A, Boroni F, Benarese M, Sarnico I, Ghisi V, Bresciani LG, et al. NF-kappaB pathway: a target for preventing beta-amyloid (Abeta)-induced neuronal damage and Abeta42 production. Eur J Neurosci 2006;23:1711-20.
DOI
|
7 |
Lin W, Ding M, Xue J, Leng W. The role of TLR2/JNK/ pathway in amyloid peptide-induced inflammatory response in mouse NG108-15 neural cells. Int Immunopharmacol 2013;17:880-4.
DOI
|
8 |
Villapol S. Roles of peroxisome proliferator-activated receptor gamma on brain and peripheral inflammation. Cell Mol Neurobiol 2018;38:121-32.
DOI
|
9 |
Corona JC, Duchen MR. as a therapeutic target to rescue mitochondrial function in neurological disease. Free Radic Biol Med 2016;100:153-63.
DOI
|
10 |
Landreth G, Jiang Q, Mandrekar S, Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 2008;5:481-9.
DOI
|
11 |
Toba J, Nikkuni M, Ishizeki M, Yoshii A, Watamura N, Inoue T, et al. agonist pioglitazone improves cerebellar dysfunction at pre- deposition stage in APPswe/PS1dE9 Alzheimer's disease model mice. Biochem Biophys Res Commun 2016;473:1039-44.
DOI
|
12 |
Memet S. NF-kappaB functions in the nervous system: from development to disease. Biochem Pharmacol 2006;72:1180-95.
DOI
|
13 |
Kim DH, Yeo SH, Park JM, Choi JY, Lee TH, Park SY, et al. Genetic markers for diagnosis and pathogenesis of Alzheimer's disease. Gene 2014;545:185-93.
DOI
|
14 |
Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 2016;8:595-608.
DOI
|
15 |
Kang S, Lee YH, Lee JE. Metabolism-Centric Overview of the Pathogenesis of Alzheimer's Disease. Yonsei Med J 2017;58:479-88.
DOI
|
16 |
Shi ZM, Han YW, Han XH, Zhang K, Chang YN, Hu ZM, et al. Upstream regulators and downstream effectors of in Alzheimer's disease. J Neurol Sci 2016;366:127-34.
DOI
|
17 |
Cai Y, Yu X, Hu S, Yu J. A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics 2009;7:147-54.
DOI
|
18 |
Karnati HK, Panigrahi MK, Gutti RK, Greig NH, Tamargo IA. miRNAs: key players in neurodegenerative disorders and epilepsy. J Alzheimers Dis 2015;48:563-80.
DOI
|
19 |
Adlakha YK, Saini N. Brain microRNAs and insights into biological functions and therapeutic potential of brain enriched miRNA-128. Mol Cancer 2014;13:33.
DOI
|
20 |
Lukiw WJ. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. Neuroreport 2007;18:297-300.
DOI
|
21 |
Muller M, Kuiperij HB, Claassen JA, Kusters B, Verbeek MM. MicroRNAs in Alzheimer's disease: differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiol Aging 2014;35:152-8.
DOI
|
22 |
Jiang Q, Heneka M, Landreth GE. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs 2008;22:1-14.
DOI
|
23 |
Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D, De Strooper B. Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J Neurosci 2004;24:10908-17.
DOI
|
24 |
Kitamura Y, Shimohama S, Koike H, Kakimura Ji, Matsuoka Y, Nomura Y, et al. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. Biochem Biophys Res Commun 1999;254:582-6.
DOI
|
25 |
Inestrosa NC, Godoy JA, Quintanilla RA, Koenig CS, Bronfman M. Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling. Exp Cell Res 2005;304:91-104.
DOI
|
26 |
Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 2003;23:9796-804.
DOI
|
27 |
d'Abramo C, Massone S, Zingg JM, Pizzuti A, Marambaud P, Dalla Piccola B, et al. Role of peroxisome proliferator-activated receptor gamma in amyloid precursor protein processing and amyloid beta-mediated cell death. Biochem J 2005;391(Pt 3):693-8.
DOI
|
28 |
de la Monte SM, Wands JR. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J Alzheimers Dis 2006;9:167-81.
DOI
|
29 |
Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 2000;20:558-67.
DOI
|
30 |
Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, et al. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A 2006;103:443-8.
DOI
|
31 |
Fakhfouri G, Ahmadiani A, Rahimian R, Grolla AA, Moradi F, Haeri A. WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR- pathway. Neuropharmacology 2012;63:653-66.
DOI
|
32 |
Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014;13:614-29.
DOI
|
33 |
Chen YC, Wu JS, Tsai HD, Huang CY, Chen JJ, Sun GY, et al. Peroxisome proliferator-activated receptor gamma (PPAR- ) and neurodegenerative disorders. Mol Neurobiol 2012;46:114-24.
DOI
|
34 |
Schmidt K. Clinical dementia rating scale. In: Michalos AC, editor. Encyclopedia of quality of life and well-being research. Dordrecht: Springer; 2014. p.957-60.
|
35 |
Mitchell AJ. The Mini-Mental State Examination (MMSE): update on its diagnostic accuracy and clinical utility for cognitive disorders. In: Larner AJ, editor. Cognitive screening instruments. Cham: Springer; 2017. p.37-48.
|
36 |
Krichevsky AM, Kosik KS. Neuronal RNA granules: a link between RNA localization and stimulation-dependent translation. Neuron 2001;32:683-96.
DOI
|
37 |
Long JM, Ray B, Lahiri DK. MicroRNA-153 physiologically inhibits expression of amyloid- precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients. J Biol Chem 2012;287:31298-310.
DOI
|
38 |
Reddy PH, Tonk S, Kumar S, Vijayan M, Kandimalla R, Kuruva CS, et al. A critical evaluation of neuroprotective and neurodegenerative MicroRNAs in Alzheimer's disease. Biochem Biophys Res Commun 2017;483:1156-65.
DOI
|
39 |
Femminella GD, Ferrara N, Rengo G. The emerging role of microRNAs in Alzheimer's disease. Front Physiol 2015;6:40.
|
40 |
Millan MJ. Linking deregulation of non-coding RNA to the core pathophysiology of Alzheimer's disease: an integrative review. Prog Neurobiol 2017;156:1-68.
DOI
|
41 |
Guidi M, Muinos-Gimeno M, Kagerbauer B, Marti E, Estivill X, Espinosa-Parrilla Y. Overexpression of miR-128 specifically inhibits the truncated isoform of NTRK3 and upregulates BCL2 in SHSY5Y neuroblastoma cells. BMC Mol Biol 2010;11:95.
DOI
|
42 |
Absalon S, Kochanek DM, Raghavan V, Krichevsky AM. MiR-26b, upregulated in Alzheimer's disease, activates cell cycle entry, tauphosphorylation, and apoptosis in postmitotic neurons. J Neurosci 2013;33:14645-59.
DOI
|
43 |
McSweeney KM, Gussow AB, Bradrick SS, Dugger SA, Gelfman S, Wang Q, et al. Inhibition of microRNA 128 promotes excitability of cultured cortical neuronal networks. Genome Res 2016;26:1411-6.
DOI
|
44 |
Tiribuzi R, Crispoltoni L, Porcellati S, Di Lullo M, Florenzano F, Pirro M, et al. miR128 up-regulation correlates with impaired amyloid (1-42) degradation in monocytes from patients with sporadic Alzheimer's disease. Neurobiol Aging 2014;35:345-56.
DOI
|